RecruitingNCT06862700

Effect of Reduced Vasopressors on Mortality in ECMO-supported Cardiogenic Shock Patients

Association Between Vasopressor Exposure Levels and 30-Day Mortality in Patients Receiving ECMO Support for Cardiogenic Shock: A Prospective Multicenter Cohort Study

Sponsor

Xiaotong Hou

Enrollment

534 participants

Start Date

Feb 26, 2025

Study Type

OBSERVATIONAL

Conditions

Heart Failure Cardiogenic Shock Extracorporeal Membrane Oxygenation Vasopressors Hemodynamic Management Critical Care

Summary

The goal of this observational study is to learn about the association between vasopressor exposure levels and outcomes in adults with cardiogenic shock receiving VA-ECMO. The main question it aims to answer is: Does reduced exposure to vasopressors lower the 30-day mortality in patients with cardiogenic shock when receiving ECMO support? Participants who are receiving ECMO support for cardiogenic shock as part of their regular medical care will have their data collected, including information about their vasopressor use and mortality outcomes, over the course of the study.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at whether using lower doses of vasopressor medicines (drugs that raise blood pressure) in patients on a heart-lung bypass machine called VA-ECMO during severe cardiogenic shock (when the heart is too weak to pump blood) reduces the risk of death. **You may be eligible if...** - You are 18 or older - You have cardiogenic shock (heart unable to pump enough blood) requiring VA-ECMO support - This is your first time on ECMO - You are on venoarterial ECMO (VA-ECMO) as the initial support mode **You may NOT be eligible if...** - You are under 18 years old - You have severe pulmonary hypertension (high pressure in the lung arteries) - You are on vasopressors for reasons other than cardiogenic shock - There is a significant amount of missing medical data Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERVasopressor Exposure Levels

This is an observational study with no active intervention. The study evaluates the association between natural variations in vasopressor exposure levels (measured by Vasoactive-Inotropic Score, VIS) and clinical outcomes in patients receiving VA-ECMO for cardiogenic shock.

Locations(1)

Beijing Anzhen Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06862700

Related Trials

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

NCT06424288653 locations

Impact of Optimized Pacing Strategies on Clinical and Hemodynamic Outcomes in Heart Failure Patients With Pacemaker

NCT075631531 location

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

NCT06935370638 locations

HARMONY Trial : To Evaluate a Therapeutic and Monitoring Device(NOVAtria System) for Heart Failure Management

NCT074022391 location

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

NCT06991257135 locations